Exec clinic people with purple accent lettering

The Leadership Meeting Agenda

April 24, 2026 - New York Times Building, NYC

Biotech Companies: A Breed Apart

8:00-9:00am

Registration and Networking Breakfast

9:00-9:05am

Welcome and Opening Remarks
  • Sara Jane Demy, Founder & CEO, Demy-Colton
  • 9:05-9:45am

    Fireside Chat
    Leading for the Long Term: The Art of Biotech

    Great biotech leaders are unafraid of the unknown—they take risks, rebound from failure, balance a multitude of demands, and stay driven by a passion for curing disease. They cultivate teams who share these same qualities. This fireside chat will explore how they handle uncertainty, sustain long-term vision, and lead organizations that turn science into real patient impact.

    Interviewer:
  • Sara Jane Demy, CEO & Founder, Demy-Colton
  • Interviewee:
  • Sharon Mates, Co-Founder, Former Chairman & CEO, Intra-Cellular Therapies, Inc
  • 9:50-10:35am

    Leadership in the Trenches: Navigating the Complexity of Today

    With major shifts in healthcare policy and the financial climate, biotech leaders face new realities on multiple fronts. With financing still tight, new regulatory and access pressures are emerging. Biotech leaders must adapt fast. Gain candid perspectives on managing volatility, sustaining momentum, and charting a path forward.

    Moderator:
  • Dawn Bell, Biotech Executive, CEO & Board Director
  • Discussants:
  • Jacqueline Kim Blechinger, Founder, Counterpoint B-1
  • Laurence Blumberg, CEO, Biotechnology Executive, Lecturer, Weill Cornell Medical Center
  • 10:35-10:50am

    Networking Break

    10:50-11:50am

    Money, Money, Money: Fundraising & Financial Strategy are Key to Success

    From raising early-stage private capital to going public, we’ll break down how to approach fundraising, handle cash flow pressures, plan for milestones, and adjust your operational footprint as conditions shift.
    Moderator:
  • Dennis Purcell, Founder, Aisling Capital
  • Discussants:
  • Jay Campbell, Life Sciences Executive, CBO, CFO & Advisory Board Member
  • Eric Heil, Managing Partner, Medical Excellence Capital
  • Peter Reikes, Former Senior Strategy Advisor, Advanced Research Projects Agency for Health (ARPA-H)
  • Brian Swanson, Senior Managing Director, Investment Banking, Leerink Partners
  • 11:55am-12:40pm

    Managing Your Assets: Advance, Partner or Shelve?

    A practical look at advancing, or pausing, your programs across Phase 1–3 development. We’ll cover topics like clinical trial planning essentials (patient population, sites, advocacy groups, funding), how to work with the new FDA, and when to bring in vendors to support your strategy and decision-making.
     Moderator:
  • Ed Saltzman, Senior Strategic Advisor, Lumanity
  • Discussants:
  • Nouhad Husseini, SVP, Head of Business Development and Corporate Strategy, Regeneron
  • Sangeetha Ransagar, Executive Director, NJ Helix Innovation Hub Powered by Portal
  • 12:40-1:40pm

    Networking Lunch

    1:40-2:25pm

    Clear, Impactful Communications: A Mission-Critical Task for Biopharma Leaders

    Welcome to the biopharma C-suite, where your audience engagement as a leader now involves multiple, diverse stakeholders: board members, investors, employees, strategic partners, and others. Communicating effectively with each audience is essential to building trust and driving momentum at every stage of your company’s growth. This discussion explores best practices and lessons learned by executives with different backgrounds, including those who transitioned from the lab to the corner office. The best leaders in our industry are, ultimately, dynamic, convincing, effective communicators.

    Moderator:
  • David Schull, President, Russo Partners
    Discussants:
  • Dawn Bell, Biotech Executive, CEO & Board Director
  • Will Ho, CEO, In8bio
  • Arun Swaminathan, CEO, Coya Therapeutics
  • Lauren Walrath, Head, US Communications & Media, Organon
  • 2:30-3:15pm

    The Board: A Huge Asset if Managed with Care

    Your board can help you raise money, introduce you to partners, evaluate and manage clinical development options. Managing board dynamics requires that you understand the motivations and interests of each board member to get the most out of them.

    Moderator:
  • Mark Kessel, Chairman of the Board, Particles for Humanity
  • Discussants:
  • Jay Campbell, Life Sciences Executive, CBO, CFO & Advisory Board Member
  • Robert Masella, Partner, Co-Chair, Public M&A, Life Sciences M&A, Goodwin
  • Jeffrey Meckler, Former CEO, Indaptus, Former CEO, Intec, Former CEO, CoCrystal
  • Evonne Sepsis, Founder & Managing Partner, ESC Advisors
  • 3:15-3:30pm

    Networking Break

    3:30-4:15pm

    Navigating Extremes: Managing Success and Dealing with Crisis

    Financial volatility, a failed trial, a successful trial, shifting narratives, team stability, stakeholder alignment—leaders today must deal with success and crisis, often in rapid succession. It’s about having a backup plan (and a backup for the backup) while finding ways to rise from the ashes. An open, unguarded conversation about leading through uncertainty with agility and purpose.

    Moderator:
  • Arda Ural, Americas Life Science Leader, Ernst & Young (EY)
  • Discussants:
  • Jacqueline Kim Blechinger, Founder, Counterpoint B-1
  • Laurence Blumberg, CEO, Biotechnology Executive, Lecturer, Weill Cornell Medical Center
  • Will Ho, CEO, IN8bio
  • 4:20-5:00pm

    Fireside Chat: Biotech in the Balance

    Interviewer:
  • Sara Jane Demy, Founder & CEO, Demy-Colton
  • Interviewee:
  • Jeremy Levin, Chairman of the Board, Ovid Therapeutics & Author: Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust
  • 5:00-6:00pm

    Networking Reception
    Executive Clinic Sponsor Page for Website Goodwin

    Sponsor This Event!